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Abstract
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No studies have investigated dietary differences between head and neck squamous cell carcinoma
(HNSCC) patients with human papillomavirus (HPV)-positive tumors and patients with HPVnegative tumors. This study was designed to investigate the relationship between diet and HPV
status in HNSCC patients. Cases of HNSCC were recruited from 2 clinical centers participating in
the University of Michigan Head and Neck Specialized Program of Research Excellence
(SPORE). HPV tissue genotyping was performed, and epidemiological and dietary data collected.
Multivariable logistic regression tested whether pretreatment consumption of 12 selected
micronutrients was significantly associated with HPV-positive status in 143 patients newly
diagnosed with cancer of the oral cavity or pharynx. After controlling for age, sex, body mass
index, tumor site, cancer stage, problem drinking, smoking, and energy intake, significant and
positive associations were observed between vitamin A, vitamin E, iron, β-carotene, and folate
intake and HPV-positive status (Ptrend < 0.05), suggesting that diet may be a factor in the
improved prognosis documented in those with HPV-positive HNSCC. Dietary differences by HPV
status should be considered in prognostic studies to better understand the influence of diet on
HNSCC survival.

INTRODUCTION

NIH-PA Author Manuscript

While tobacco and concurrent alcohol use accounts for the majority of all cases of head and
neck squamous cell carcinoma (HNSCC) in many populations, the oncogenic human
papillomavirus (HPV)-16 contributes to a distinct subtype of the disease (1-6). HPVassociated tumors accounted for more than 50% of the squamous cell carcinomas of the
oropharynx in the United States prior to 2005 (5). Recent data show that the proportion of
HPV-positive oropharynx cancers is continuing to increase. Among a cohort of
oropharyngeal cancer patients followed by our group from 1999 to 2002, 64% entered into a
clinical trial of induction chemotherapy followed by concurrent cisplatin and radiation had
HPV-positive tumors (2). In the consecutive cohort entered from 2002 to 2007 into our
subsequent trial of concurrent cisplatin, taxol, and radiation, 82% of the oropharynx cancers
contained high-risk HPV (7). The proportion of HPV-positive head and neck cancers at
other sites is less clear, with our estimates falling below 20%. The accumulating evidence
suggests that these two distinct subtypes of HNSCC are characterized by different risk
profiles and clinical outcomes. HPV-positive tumors are typically found in younger
individuals with less exposure to tobacco and have been associated with improved long-term
survival when compared with HPV-negative, more strongly tobacco-related tumors,
independent of treatment modality (7-13). HPV-positive patients with a more extensive
smoking history may experience reduced disease-specific survival and increased risk of
disease recurrence than their non-smoking counterparts (7,14).
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Risk factors for HNSCC other than tobacco use and HPV infection have been identified.
Inadequate intake of certain micronutrients and foods may contribute to the development of
HNSCC, while adequate intake may be protective (15). Evidence for inverse associations
between oral and pharyngeal cancer and dietary consumption of several micronutrients
includes associations for the antioxidant vitamins A, C, E, and carotenoids (15-18); minerals
such as iron, calcium, and zinc (15,16,18-21); folate (16,22); and riboflavin (19-21). Several
studies have reported inverse associations between oral and pharyngeal cancer risk and fruit
and vegetable intake (17,19,23-25). Furthermore, low fruit intake may be associated with
reduced survival in patients diagnosed with HNSCC (26), and high vegetable intake may
reduce the risk of recurrence and mortality in oral cancer patients (27).
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Although improved prognoses have been documented in HNSCC patients with HPVpositive tumors, the basis for this survival advantage has not been well established. Whether
or not diet plays an independent role in HNSCC survival is unknown. Individuals with HPVassociated tumors tend to lead healthier lifestyles—they are younger, have lower exposure to
tobacco and alcohol, and have higher education and socioeconomic status (SES) than
individuals with tobacco-related tumors (1). These data suggest that diet may differ between
subjects with HPV-positive tumors and subjects with HPV-negative tumors, as diet quality
is generally associated with SES and lifestyle (28,29). Hence, this case-only analysis was
conducted to determine if there are differences in pretreatment intake of key micronutrients
between newly diagnosed HPV-positive and negative HNSCC patients.

METHODS
This was a cross-sectional study of patients enrolled in the University of Michigan Head and
Neck Cancer, Specialized Program of Research Excellence (SPORE). The independent
variables were total intake from food and supplements of 12 micronutrients: vitamins A, C,
D, B12, β-carotene, calcium, iron, zinc, copper, riboflavin, and folic acid. Confounding
variables included age, sex, race/ethnicity, educational level, body mass index [BMI =
weight(kg)/height(m)2], smoking, problem drinking, tumor site, and cancer stage. The
outcome variable was HPV status (positive or negative).
Study Sample

NIH-PA Author Manuscript

Newly diagnosed patients with squamous cell carcinoma of the head and neck were
recruited to participate in this study. Patients were recruited from the Ann Arbor Veterans
Affairs Hospital and the University of Michigan Hospital. Exclusion criteria included: 1)
<18 yr of age; 2) pregnant; 3) non-English-speaking; 4) diagnosed as mentally unstable; 5) a
diagnosis of another non-upper aerodigestive tract cancers (such as thyroid or skin cancer);
or 6) a previous diagnosis and treatment for head and neck cancer. Out of 1,185 patients
approached, 934 consented to participate yielding a response rate of 79%.
Tumors with adequate tissue for microdissection were available from 205 patients, and 203
of 205 (99%) had amplifiable DNA as assessed by PCR amplification of beta-globin. Of
these 203 patients, 193 had completed a self-administered food frequency questionnaire
(FFQ) at presentation (30). No laryngeal tumors contained integrated HPV. Therefore, 50
individuals with larynx tumors were excluded, leaving a total of 143 subjects in the current
analysis. Human subjects’ approval was received from the institutional review boards at
each institution.
Procedures
Research assistants recruited patients to the study in the waiting rooms of otolaryngology
clinics. Informed consent was obtained and epidemiologic data were collected using a self-
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administered questionnaire, as has been previously described (31). A medical record review
was completed for each study participant. Dietary intake was collected using a selfadministered, semiquantitative FFQ, validated for use in several populations (30,32,33).
Tumor blocks were recut for uniform histopathologic review and microdissection, with the
first and last slides of a series of 12 reviewed by a qualified pathologist to confirm the
original diagnosis and to circle areas for microdissection. Percent cellularity was estimated
for each tumor, and areas with >70% cellularity of cancer were designated for cancer
microdissection.
HPV genotyping was performed using the GP5+/GP6- PCR reverse line blot (RLB) method
for 37 HPV types (34,35). Adequacy of amplifiable DNA was assessed using PCR for
betaglobin as a positive control. All runs included positive and negative controls for HPV, as
well as water controls to exclude the possibility of contamination. All HPV assays were
repeated at least twice for quality assurance and quality control, with perfect
correspondence. A subset of tumors also had frozen tumor available, and independent HPV
assays were performed on these tumors.
Measures
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The 131-item FFQ was designed to assess respondents’ usual dietary intake from food and
supplements over the past year. Total energy and nutrient intake was estimated by summing
intakes from each food based on the given standard portion size, reported frequency of
consumption, and nutrient content of each food item (33). As the FFQ has not been validated
in HNSCC populations, reliability of energy reporting using this tool is unknown. Because
the majority of patients had advanced tumors (Stage 3 or 4) upon entering the study, selfreported dietary intake may be reflective of recent dietary changes due to disease
progression, rather than actual intake over the past year. Therefore, we chose to use a
surrogate measure of energy intake in this analysis as opposed to self-reported energy intake
from the FFQ. The population-adjusted total energy expenditure (PATEE), developed by
Hebert et al., is based on an individual’s basal metabolic rate (BMR, as calculated by the
Harris-Benedict equation) and is weighted by age group-specific median caloric intakes as
reported by the National Health and Nutrition Examination Survey (36,37). PATEE was
developed for use in the Women’s Health Initiative (37). Originally designed for use as a
proxy when reported FFQ energy intake (FFQEI) data are missing (38), the current
refinement has been validated in a cohort of subjects on which total energy intake was
estimated from doubly labeled water (37). The PATEE variable was calculated for each
individual and Pearson correlation coefficients were computed to measure the strength of the
linear relationship between FFQEI and PATEE, which was found to be excellent (b = 0.92;
SEb = 0.20) (37).
Smoking data permitted analysis by “current-past-never” smoking and cumulative packyears. Cumulative pack-years was coded as ≤30 pack-years or >30 pack-years (median) to
avoid problems due to non-normality. Alcohol consumption was measured using the
previously validated Alcohol Use Disorders Identification Test (AUDIT) (39). An AUDIT
score ≥8 was considered problem drinking. Tumor site was recorded from operative notes
and surgical pathology forms. For the purposes of data analysis, tumor site was categorized
into oral cavity, pharynx, or larynx. Cancer stage was categorized a priori into 3 groups,
with Stages 1 and 2 considered together, and Stage 3 and Stage 4 considered separately,
enhancing power of comparisons by stage.
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Descriptive statistics were generated for all variables (means and frequencies), and bivariate
analyses were conducted to determine differences in demographic characteristics between
individuals with HPV-positive tumors and HPV-negative tumors. Student’s t-tests were
conducted to test whether the two study groups differed significantly by age and BMI. To
test whether the two groups differed significantly by sex, race, education, smoking, alcohol
problem, and tumor site, chi-square tests were performed. The Wilcoxon rank-sum test was
used to determine if the HPV-positive and HPV-negative study groups differed significantly
by tumor stage. Multivariable logistic regression models were fit to test whether
pretreatment intake of 12 select micronutrients was significantly associated with HPVpositive status. Each micronutrient was categorized into quartiles of intake from foods and
supplements and quartiles of intake from foods only. Categorical variables were created for
sex (male vs. female), tumor site (pharynx vs. oral cavity), cancer stage (Stage 1 or 2, Stage
3, Stage 4), smoking (current, past, never), and problem drinking (none vs. any). A test for
trend across increasing quartiles of total dietary intake from food and supplements was
performed with an alpha level of 0.05 considered significant. A similar test for trend was
performed for dietary intake from food sources only. Covariates adjusted for included age,
BMI, PATEE, sex, tumor site, smoking, and problem drinking. Education was considered as
a covariate but did not influence the significance of the model. A sensitivity analysis was
conducted for the association between each micronutrient with HPV status, controlling for
the remaining micronutrients. To address correlation among micronutrient intakes, a
principal components analysis was performed for the remaining micronutrients, and the top
3 factors were included in the multivariable model. In all models, these 3 factors accounted
for at least 75% of the variability in the remaining variables (77–81%). All analyses were
performed using SAS software (SAS 9.1, SAS Institute, Cary, NC).
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RESULTS
The majority of the study population was European American (93%) and male (80%). Eversmoking and problem drinking were highly prevalent in this population (77% and 31%,
respectively). Patients were more likely to have Stage 3 or Stage 4 tumors than Stage 1 or 2
at presentation to clinical centers.
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Table 1 compares epidemiologic characteristics of those patients with HPV-positive tumors
to those with HPV-negative tumors. The vast majority of HPV-positive cancers were found
in the pharynx. Individuals with HPV-positive tumors appeared to have a higher mean BMI
than those with HPV-negative tumors (27.9 kg/m2 and 26.0 kg/m2, respectively; P = 0.08).
Distribution of “ever” vs. “never” smoking did not differ significantly by HPV status. HPVpositive patients were less likely to be current smokers (P = 0.05), and tended to have
smoked for less than the median number of pack-years (P = 0.07). A greater percentage of
individuals with HPV-negative tumors reported they had an alcohol problem than did
individuals with HPV-positive tumors (36.2% and 18.4%, respectively; P = 0.04).
Distribution of HPV status did not differ significantly with respect to age, sex, cancer stage,
race, or highest education attained.
Mean estimated BMR differed significantly between HPV-positive and HPV-negative
individuals (mean = 1534 and 1446, respectively; P = 0.02), while mean FFQEI and PATEE
did not differ significantly by HPV status. FFQEI and PATEE were not well correlated with
one another (r = 0.17, r = 0.09, and r = 0.19 for total, HPV-positive, and HPV-negative,
respectively). However, controlling for FFQEI instead of PATEE in the multivariable
models did not significantly change the quartile-specific odds ratios and Ptrend for each
respective micronutrient (results not shown).

Nutr Cancer. Author manuscript; available in PMC 2012 July 08.

Arthur et al.

Page 6

NIH-PA Author Manuscript

Because micronutrients were modeled as quartiles of intake, the cut point for each quartile is
listed in Table 2 for total nutrient intake from food and supplements and for nutrient intake
from food sources alone. After controlling for age, sex, BMI, tumor site, cancer stage,
smoking, problem drinking, and PATEE, a significant association was observed between
HPV-positive status and increasing quartiles of intake from food and supplements for
vitamin A (OR = 22.41 for the highest quartile versus the lowest quartile; Ptrend = 0.003),
vitamin E (OR = 3.84; Ptrend = 0.04), β-carotene (OR = 3.86; Ptrend = 0.02), iron (OR =
14.45; Ptrend = 0.003) and folate (OR = 8.97; Ptrend = 0.02) (Table 3). Associations between
HPV status and total intake of vitamin C, vitamin D, calcium, zinc, copper, riboflavin, and
vitamin B12 were not significant. The results did not substantially differ when considering
micronutrient intakes from food sources alone. After adjustment for the remaining
micronutrients in a sensitivity analysis, vitamin A and iron remained significant predictors
of HPV status.

DISCUSSION
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In this study of HNSCC patients, we observed a significant and positive association across
quartiles of intake and HPV-positive status for total nutrient intake from food and
supplements, and intake from food sources alone of vitamin A, vitamin E, β-carotene, iron,
and folate. These results indicate that patients with HPV-positive tumors consume
significantly higher levels of key micronutrients with anticancer functions compared to
patients with HPV-negative tumors. Sensitivity analyses indicated that, regardless of overall
micronutrient intake, vitamin A and iron predicted HPV status. HPV-positive head and neck
cancer cases generally have lifestyle characteristics that are associated with better overall
health than the lifestyle characteristics of HPV-negative patients. For example, HPVpositive patients typically have a higher SES and less lifetime exposure to tobacco and
alcohol compared to HPV-negative patients. Higher SES and less tobacco use and alcohol
consumption are generally associated with better overall diet quality (28,29). This is also
seen in our study, where HPV-positive cases have a less extensive history of smoking and
alcohol abuse than do HPV-negative cases.
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There are other potential explanations for the observed micronutrient differences between
HPV-positive and HPV-negative cases. A previous study reported that HPV-16 seronegative
individuals with greater fruit or citrus intake were significantly less likely to develop
HNSCC than those with low fruit or citrus intake. On the other hand, though
counterintaitive, HPV-16 seropositive individuals with greater citrus fruit consumption were
significantly more likely to develop HNSCC than HPV-16 seropositive individuals
consuming lower amounts of citrus fruit. The authors hypothesized a mechanism by which
citrus fruit and other highly acidic foods may erode the mucosal lining of the gastrointestinal
tract, increasing the probability of HPV infection (40). Higher prediagnosis intake of the
micronutrients observed to be significantly associated with HPV-positive status in the
currents study, or foods rich in the observed micronutrients, could make an individual more
susceptible to oral HPV infection and therefore more at risk for developing HNSCC due to
HPV.
Another study reported that higher plasma levels of carotenoids were associated with a 43%
to 50% reduction in the risk of initial anal HPV infection, but lower levels of carotenoids
and retinol were associated with clearance of persistent anal HPV infection (41). This
evidence is consistent with our finding that higher intakes of vitamin A and ß-carotene are
associated with HPV-positive HNSCC.
Higher intakes of vitamin A, vitamin E, β-carotene, iron, and folate may independently
influence the better prognosis of HPV-positive patients and this possibility should be
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explored further. There are several mechanisms by which adequate dietary intake of vitamin
A, β-carotene, iron, and folate may contribute to better clinical outcomes in HNSCC
patients. Two previous studies reported that higher levels of plasma carotenoids in HNSCC
patients before and after radiotherapy were associated with improved progression-free
survival, as well as with overall survival (42,43). Vitamin A in the form of retinoic acid is
believed to regulate epithelial cell differentiation through its effects on gene expression.
Homodimer and heterodimer complexes produced during metabolism of vitamin A bind to
retinoic acid response elements (RARE) in promoter regions of specific genes, resulting in
modification of cellular processes important in controlling carcinogenesis such as apoptosis
(44,45). Furthermore, retinoic acid and β-carotene may play a role in preventing
uncontrolled cell growth by preserving gap junction communication between cells (45-47).
β-carotene also functions as an antioxidant, quenching singlet oxygen species and
scavenging peroxyl radicals, thus helping to prevent cellular damage (48).
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Recent findings of our research group show that HPV-positive patients may have enhanced
adaptive immunity, which is associated with improved tumor response to chemotherapy
when compared to HPV-negative patients (49). As reviewed by Wintergerst et al., vitamin
A, iron, and folate each play mechanistic roles in immune function. Vitamin A is necessary
for both adaptive and innate immunity and is involved in the anti-inflammatory response of
T-helper cell 2 (Th2). A state of vitamin A deficiency is associated with reduced natural
killer (NK) cell activity and antigen-specific response by Th1 cells (50). Differentiation and
proliferation of NK and Th cells are modulated by cellular iron and therefore do not
proliferate as rapidly under a state of iron deficiency (50). Folate works synergistically with
vitamins B6 and B12 to supply 1-carbon units during synthesis of nucleotides and proteins.
A deficiency consequently results in decreased proliferation and number of circulating
lymphocytes. Deficiency also is associated with an increased CD4+/CD8+ ratio (50).
Associations between intake of vitamin A, folate, iron, and immune function in HNSCC
patients should be investigated, as higher dietary intake from food, supplements, or both
may play a key role in the improved immune function and prognosis of individuals with
HPV-positive tumors.
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Finally, while there was no significant difference between HPV-positive and HPV-negative
patients reporting “ever” vs. “never” smoking, there was a marginally significant difference
between the two groups when comparing current smoking and pack-years of overall
exposure. This suggests that although the same proportion of HPV-positive patients as HPVnegative patients have smoked at some point in their lives, HPV-positive patients were more
likely to have quit smoking and thus have less lifelong exposure to tobacco. While
speculative, it also could indicate that smoking at an earlier age concurrent with HPV
infection is associated with development of HNSCC. We did not have the statistical power
to detect an interaction between diet and smoking, but this relationship should be examined
in the future.
Findings should be interpreted in light of several limitations. Although a common concern
about HNSCC patients is inadequate micronutrient intake at the time of diagnosis—with the
exception of vitamin E, vitamin D, and calcium—at least 50% of our study population was
consuming adequate amounts of each micronutrient (based on recommended daily
allowances and adequate intake values) when considering intake from diet and supplements.
However, reported intake may include some misclassification due to difficulty in recalling
and quantifying foods consumed over the previous year. Our study does not include
controls, preventing the ability to estimate risk of disease due to diet. Nevertheless, we note
consistency with case-control studies of diet and HNSCC, where protective micronutrients
are associated with HPV-positive status of the tumor.
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In conclusion, higher intakes of key micronutrients are associated with HPV-positive
HNSCC. When consumed at higher levels these micronutrients may increase the
susceptibility of patients to HPV infection. Also, it is possible that higher intakes of the
micronutrients observed in this study to be associated with HPV status play an independent
role in the improved prognoses of HPV-positive HNSCC patients compared to HPVnegative patients. This hypothesis should be examined in the future, as it may present an
avenue to improve survival in patients with this deadly cancer.
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TABLE 1

Baseline characteristics by HPV status (N = 143)

NIH-PA Author Manuscript

Total

HPV + No. (%)

HPV – No. (%)

N

Demographics

143

38 (26.6)

105 (73.4)

P Value

Age (SD)†

57.9

58.9 (7.4)

57.9 (10.7)

0.99

Male

115

34 (89.5)

81 (77.1)

0.10

Female

28

4 (10.5)

24 (22.9)

White

133

37 (97.4)

96 (91.4)

Black

4

1 (2.6)

3 (2.9)

American Indian

6

0 (0)

6 (5.7)

≤High school/GED

70

19 (50)

51 (48.5)

Some college

73

19 (50)

54 (51.4)

26.5 (5.8)

27.9 (4.6)

26.0 (6.1)

0.08

Current

44

7 (18.4)

37 (35.2)

0.15

Former

66

21 (55.3)

45 (42.9)

Never

33

10 (26.3)

23 (21.9)

≥Median

59

11 (28.9)

48 (45.7)

<Median

84

27 (71.1)

57 (54.3)

Yes

45

7 (18.4)

38 (36.2)

No

98

31 (81.6)

67 (63.8)

Oral cavity

35

1 (2.6)

34 (32.4)

Pharynx

108

37 (97.4)

71 (67.6)

1, 2

16

1 (2.6)

15 (14.3)

3

32

9 (23.7)

23 (21.9)

4

95

28 (73.7)

67 (63.8)

Sex††

Race††
0.38

Highest education††

NIH-PA Author Manuscript

BMI in kg/m2 (sd)†

0.88

Smoking††

Pack-years (median = 30)††
0.07

Alcohol problem††
0.04*

Site††
<0.01*

NIH-PA Author Manuscript

Stage‡
0.17

*

Indicates significance at P < 0.05.

†

Student’s t-test.

††

Chi-square test or Fisher’s exact test was used as appropriate.

‡

Wilcoxon rank-sum test.
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6.6
1512.4
158.5
619.5
10.7
9.3
1.1
2.2
6.4

Vitamin E (mg/day)

β-carotene (μg/day)

Vitamin D (IU/day)

Calcium (mg/day)

Iron (mg/day)

Zinc (mg/day)

Copper (μg/day)

Riboflavin (mg/day)

Vitamin B12 (μg/day)
381.3

81.4

Vitamin C (mg/day)

Folic acid (μg/day)

5406.2

25

586.7

10.7

3.2

1.8

13.9

15.9

913.7

345.5

2483.7

13.4

146.6

8589.1

50

816.7

17.9

4.5

3.2

23.1

24.12

1351.1

585.8

4342.1

27.3

262.5

12601.5

75

Food and Supplements Percentile

Vitamin A (IU/day)

Nutrient

294.2

4.7

1.7

1.1

8.6

9.8

537.9

100.7

1296.3

4.9

57.1

3957.3

25

399.7

7

2.4

1.5

11.7

13.6

769.7

171

2127.3

6.9

97.4

6074.2

50

75

547.8

10.1

3.1

2

16.2

18.8

1117.3

255.7

3621.5

10

154.7

8984.2

Food Percentile

Quartile designations of nutrient intake among HNSCC patients (N = 143)
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22.41 (3.57–140.84)

Quartile 4

3.38 (0.80–14.24)

2.82 (0.66–12.13)

Quartile 3

Quartile 4

3.33 (0.87–12.71)

3.84 (1.04–4.16)

Quartile 3

Quartile 4

5.89 (1.51–23.01)

3.86 (1.00–14.99)

Quartile 3

Quartile 4

1.67 (0.50–5.60)

1.15 (0.33–3.98)

Quartile 3

Quartile 4

0.78 (0.23–2.64)

0.61 (0.15–2.38)

2.09 (0.58–7.56)

Quartile 2

Quartile 3

Quartile 4

Calcium

0.52 (0.15–1.79)

Quartile 2

Vitamin D

1.18 (0.25–5.53)

Quartile 2

β-carotene

2.39 (0.65–8.73)

Quartile 2

Vitamin E

4.09 (1.02–16.35)

Quartile 2

0.308

0.501

0.018*

0.041*

0.261

0.003*

P Trend

Quartile 4

Quartile 3

Quartile 2

Folic Acid

Quartile 4

Quartile 3

Quartile 2

Vitamin B12

Quartile 4

Quartile 3

Quartile 2

Riboflavin

Quartile 4

Quartile 3

Quartile 2

Copper

Quartile 4

Quartile 3

Quartile 2

Zinc

Quartile 4

Quartile 3

Quartile 2

Iron

Nutrient

8.97 (1.95–41.19)

3.54 (0.89–14.09)

6.07 (1.47–25.07)

1.95 (0.59–6.45)

2.05 (0.56–7.56)

1.44 (0.44–4.67)

2.80 (0.79–9.89)

3.12 (0.81–12.05)

1.93 (0.55–6.81)

1.35 (0.39–4.70)

2.41 (0.71–8.18)

1.03 (0.30–3.62)

3.17 (0.94–10.72)

1.34 (0.37–4.88)

1.99 (0.56–7.14)

14.45 (3.04–68.73)

1.86 (0.39–8.93)

4.30 (0.97–19.02)

OR (95% CI)

0.015*

0.229

0.093

0.344

0.107

0.003*

P Trend

Subjects were categorized into quartiles based on reported nutrient intake.

†

Indicates test for trend significant at P < 0.05 adjusting for age, sex, BMI, tumor site, energy intake, problem drinking, and pack-years.

*

5.72 (1.00–33.00)

Quartile 3

Vitamin C

11.18 (1.88–66.32)

OR (95% CI)

Quartile 2

Vitamin A

Nutrient

Adjusted odds of HPV+ status categorized by quartiles of total nutrient intake among oral and pharyngeal HNSCC patients (N = 143)†
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